Rezolute, Inc (RZLT)

Etorro trading 970x250
Rezolute, Inc (RZLT) Logo

About Rezolute, Inc

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. Address: 201 Redwood Shores Parkway, Redwood City, CA, United States, 94065

Rezolute, Inc News and around…

Latest news about Rezolute, Inc (RZLT) common stock and company :

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
12 May, 2022 Yahoo! Finance

Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from Phase 1b multiple-ascending dose study of RZ402 enable Phase 2 proof-of-concept study initiation later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinic

Rezolute to Host Corporate Update Call on May 4, 2022
04 May, 2022 Yahoo! Finance

Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ETREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management will be hosting a corporate update call. The call will highlight recent pipeline advancements and continued

Rezolute, Inc. Announces Closing of Registered Direct Offering
04 May, 2022 Yahoo! Finance

REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu

Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events
02 May, 2022 FinancialContent

Rezolute Inc(NASDAQ: RZLT)unveiled resultsfrom its Phase 2b RIZE study of RZ358 in patients with congenital ...

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
02 May, 2022 Yahoo! Finance

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the pricing of an underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-f

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
01 May, 2022 Yahoo! Finance

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual MeetingHighly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemiaStudy exceeded expectations for correction of hypoglycemia across multiple metrics, including hypoglycemia events and time in hypoglycemiaPredictable and dose-dependent exposures with a c

RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
26 Apr, 2022 Yahoo! Finance

Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced a late-breaking oral presentation of its Phase 2b RIZE Study Topline Data of RZ358 in congenital hyperin

12 Health Care Stocks Moving In Monday's Pre-Market Session
18 Apr, 2022 FinancialContent

Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
07 Apr, 2022 FinancialContent

Gainers IMAC Holdings (NASDAQ:IMAC) shares increased by 60.0% to $1.6 during Thursday's pre-market session. The market value of their ...

Rezolute Joins the Rare Disease Company Coalition
29 Mar, 2022 Yahoo! Finance

Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseasesREDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that it has joined the Rare Disease Company Coalition. As an alliance of life science comp

36 Stocks Moving In Friday's Mid-Day Session
25 Mar, 2022 FinancialContent

Gainers Forge Global Holdings, Inc. (NYSE: FRGE) shares jumped 66.4% to $20.70. Clever Leaves Holdings Inc. (NASDAQ: CLVR) ...

12 Health Care Stocks Moving In Thursday's After-Market Session
24 Mar, 2022 FinancialContent

Gainers Tilray Brands (NASDAQ:TLRY) shares rose 12.9% to $7.87 during Thursday's after-market session. Trading volume for this ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
23 Mar, 2022 FinancialContent

Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
23 Mar, 2022 FinancialContent

Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The ...

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
23 Mar, 2022 Yahoo! Finance

The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral presentation at a medical congress in 2Q 2022 REDWOOD CITY, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced positive data from i

58 Biggest Movers From Friday
21 Mar, 2022 FinancialContent

Gainers BEST Inc. (NYSE: BEST) shares gained 73.6% to close at $1.00. DiDi Global Inc. (NYSE: DIDI) shares jumped 59.8% to ...

45 Stocks Moving In Friday's Mid-Day Session
18 Mar, 2022 FinancialContent

Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) jumped 62.4% to $1.5500. DiDi Global Inc. (NYSE: DIDI) shares climbed 46% ...

12 Health Care Stocks Moving In Monday's Intraday Session
28 Feb, 2022 FinancialContent

Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current ...

88 Biggest Movers From Yesterday
25 Feb, 2022 FinancialContent

Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million ...

Wednesday Sector Laggards: Apparel Stores, Biotechnology Stocks
23 Feb, 2022 FinancialContent

In trading on Wednesday, apparel stores shares were relative laggards, down on the day by about 0.6%. Helping drag down the group were shares of TJX Companies (TJX), down about 5.9% and shares of Ross Stores (ROST) off about 3.8% on the day.

Rezolute Highlights Early-Stage Study Results For RZ402 In Diabetic Macular Edema
22 Feb, 2022 FinancialContent

Rezolute Inc(NASDAQ: RZLT)announced topline datafrom its Phase 1b multiple-ascending dose (MAD) study of RZ402, a ...

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
22 Feb, 2022 Yahoo! Finance

Phase 2 proof-of-concept study anticipated in 2H 2022REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced topline data from its Phase 1b multiple-ascending dose (MAD) study of RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular edema (DME).

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
09 Feb, 2022 Yahoo! Finance

Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the second quarter of fiscal 2022 ended December 31, 2021. “We have maintained excellent momentum and are on track to report topl

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
12 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter of fiscal 2022 ended September 30, 2021. “This has been a productive quarter of execution for Rezolute, with steady clinical advancement of our lead pipeline candidates, RZ358 and RZ402, in Phase 2b and Phase

InvestorNewsBreaks – Rezolute Inc. (NASDAQ: RZLT) Announces Underwritten Public Offering, Concurrent Registered Direct Offering
01 Nov, 2021 FinancialContent
Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares?
19 Oct, 2021 Yahoo! Finance

A look at the shareholders of Rezolute, Inc. ( NASDAQ:RZLT ) can tell us which group is most powerful. Large companies...

50 Biggest Movers From Yesterday
14 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Oct, 2021 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The ...

40 Stocks Moving In Wednesday's Mid-Day Session
13 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock ...

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
13 Oct, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public o

Rezolute, Inc (RZLT) is a NASDAQ Common Stock listed in , ,

970x250